We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

209 hedge funds and large institutions have $901M invested in Vir Biotechnology in 2024 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 27

13% more call options, than puts

Call options by funds: $3.04M | Put options by funds: $2.7M

1% more funds holding

Funds holding: 206 → 209 (+3)

4% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 68

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $909M → $901M (-$7.72M)

1.31% less ownership

Funds ownership: 67.13% → 65.83% (-1.3%)

Holders
209
Holders Change
+3
Holders Change %
+1.46%
% of All Funds
3.01%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
71
Reduced
68
Closed
27
Calls
$3.04M
Puts
$2.7M
Net Calls
+$342K
Net Calls Change
-$1M

Top Buyers

1
Bank of America
Bank of America
North Carolina
+$10M
2
Citigroup
Citigroup
New York
+$9.36M
3
Barclays
Barclays
United Kingdom
+$5.8M
4
O
OrbiMed
New York
+$5.49M
5
Citadel Advisors
Citadel Advisors
Florida
+$3.77M

Top Sellers

1
AllianceBernstein
AllianceBernstein
Tennessee
-$27.2M
2
Morgan Stanley
Morgan Stanley
New York
-$19.5M
3
Prudential Financial
Prudential Financial
New Jersey
-$3.29M
4
TC
TwinBeech Capital
New York
-$3.22M
5
BlackRock
BlackRock
New York
-$3.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$4.68M -$464K -45,597 -9%
EF
27
Empowered Funds
Pennsylvania
$4.64M +$353K +34,640 +8%
Invesco
28
Invesco
Georgia
$4.55M +$1.62M +158,943 +55%
Rafferty Asset Management
29
Rafferty Asset Management
New York
$4.45M +$411K +40,353 +10%
Ameriprise
30
Ameriprise
Minnesota
$3.27M +$100K +9,824 +3%
Jacobs Levy Equity Management
31
Jacobs Levy Equity Management
New Jersey
$3.14M +$169K +16,615 +6%
Hudson Bay Capital Management
32
Hudson Bay Capital Management
Connecticut
$2.89M -$50.9K -5,000 -2%
Corient Private Wealth
33
Corient Private Wealth
Florida
$2.73M +$26.8K +2,633 +1%
Capital International Investors
34
Capital International Investors
California
$2.62M – – –
Legal & General Group
35
Legal & General Group
United Kingdom
$2.55M +$68.5K +6,722 +3%
Nordea Investment Management
36
Nordea Investment Management
Sweden
$2.41M +$888K +87,190 +59%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$2.32M -$476K -46,771 -17%
N
38
Nuveen
North Carolina
$2.11M – – –
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$1.89M -$321K -31,546 -14%
Swiss National Bank
40
Swiss National Bank
Switzerland
$1.88M – – –
Public Sector Pension Investment Board (PSP Investments)
41
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$1.81M – – –
Walleye Capital
42
Walleye Capital
New York
$1.75M -$114K -11,168 -6%
SOADOR
43
State of Alaska Department of Revenue
Alaska
$1.54M -$5.28K -518 -0.3%
American Century Companies
44
American Century Companies
Missouri
$1.51M +$508K +49,897 +50%
Prudential Financial
45
Prudential Financial
New Jersey
$1.45M -$3.29M -322,760 -69%
Norges Bank
46
Norges Bank
Norway
$1.26M +$941K +92,387 +289%
AllianceBernstein
47
AllianceBernstein
Tennessee
$1.11M -$27.2M -2,671,429 -96%
RA
48
Royce & Associates
New York
$1.04M – – –
Franklin Resources
49
Franklin Resources
California
$1.04M +$897K +88,055 +593%
DA
50
Duality Advisers
Florida
$1.03M +$64.5K +6,331 +7%
1
2
3 4 5

VIR Hedge Fund Activity: Q1 2024 in Review

209 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2024, worth a combined $901M — down 0.85% from $909M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new VIR positions and 27 closed out — a net gain of 4 holders — while 71 added to existing stakes and 68 trimmed.

The largest buyer was Bank of America, adding an estimated $10M. The largest seller was AllianceBernstein, cutting an estimated $27.2M.

  • 209 institutional investors held Vir Biotechnology (VIR) as of Q1 2024, up from 206 in Q4 2023.
  • Funds reported $901M of Vir Biotechnology stock for Q1 2024, down 0.85% quarter-over-quarter.
  • 31 funds opened new Vir Biotechnology positions in Q1 2024 and 27 closed out, a net change of +4 holders.
  • The largest Vir Biotechnology buyer in Q1 2024 was Bank of America, an estimated $10M added.
  • The largest Vir Biotechnology seller in Q1 2024 was AllianceBernstein, an estimated $27.2M sold.

Based on aggregated 13F filings for Q1 2024.